Switch theme
Sign up to access all valuation multiples
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
2011
138
LTM Revenue $0.1M
LTM EBITDA -$34.8M
$24.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adagene has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$34.8M.
In the most recent fiscal year, Adagene achieved revenue of $0.1M and an EBITDA of -$31.7M.
Adagene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adagene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$34.8M | XXX | -$31.7M | XXX | XXX | XXX |
| EBITDA Margin | -46880% | XXX | -30668% | XXX | XXX | XXX |
| EBIT | -$37.0M | XXX | -$36.0M | XXX | XXX | XXX |
| EBIT Margin | -49771% | XXX | -34835% | XXX | XXX | XXX |
| Net Profit | -$35.8M | XXX | -$33.4M | XXX | XXX | XXX |
| Net Margin | -48146% | XXX | -32386% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Adagene's stock price is $2.
Adagene has current market cap of $91.4M, and EV of $24.7M.
See Adagene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.7M | $91.4M | XXX | XXX | XXX | XXX | $-0.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Adagene has market cap of $91.4M and EV of $24.7M.
Adagene's trades at 239.3x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Adagene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adagene has a P/E ratio of -2.6x.
See valuation multiples for Adagene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $91.4M | XXX | $91.4M | XXX | XXX | XXX |
| EV (current) | $24.7M | XXX | $24.7M | XXX | XXX | XXX |
| EV/Revenue | 332.3x | XXX | 239.3x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 332.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.6x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAdagene's last 12 month revenue growth is -46%
Adagene's revenue per employee in the last FY averaged $1K, while opex per employee averaged $0.3M for the same period.
Adagene's rule of 40 is -128% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Adagene's rule of X is -46995% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Adagene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -46% | XXX | -30% | XXX | XXX | XXX |
| EBITDA Margin | -46880% | XXX | -30668% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -128% | XXX | -30714% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -46995% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 27888% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34935% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adagene acquired XXX companies to date.
Last acquisition by Adagene was XXXXXXXX, XXXXX XXXXX XXXXXX . Adagene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Adagene founded? | Adagene was founded in 2011. |
| Where is Adagene headquartered? | Adagene is headquartered in United States of America. |
| How many employees does Adagene have? | As of today, Adagene has 138 employees. |
| Who is the CEO of Adagene? | Adagene's CEO is Dr. Peter Luo, PhD. |
| Is Adagene publicy listed? | Yes, Adagene is a public company listed on NAS. |
| What is the stock symbol of Adagene? | Adagene trades under ADAG ticker. |
| When did Adagene go public? | Adagene went public in 2021. |
| Who are competitors of Adagene? | Similar companies to Adagene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Adagene? | Adagene's current market cap is $91.4M |
| What is the current revenue of Adagene? | Adagene's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Adagene? | Adagene revenue growth (NTM/LTM) is -46%. |
| What is the current EV/Revenue multiple of Adagene? | Current revenue multiple of Adagene is 332.3x. |
| Is Adagene profitable? | Yes, Adagene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Adagene? | Adagene's last 12 months EBITDA is -$34.8M. |
| What is Adagene's EBITDA margin? | Adagene's last 12 months EBITDA margin is -46880%. |
| What is the current EV/EBITDA multiple of Adagene? | Current EBITDA multiple of Adagene is -0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
